Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique
Journal of Acquired Immune Deficiency Syndromes, Volume 51, No. 3, Year 2009
Notification
URL copied to clipboard!
Description
OBJECTIVES: To characterize HIV-1 diversity and transmitted drug resistance in persons with access to care and treatment in Maputo, Mozambique. METHODS: Samples were collected in 2002-2004 from 144 drug-naive patients attending public hospitals and private clinics. Plasma viremia, CD4, and CD8 cell counts were determined for each patient. The Stanford Algorithm was used for resistance genotyping on pol sequences. Subtyping was done by phylogenetic analysis. RESULTS: Most patients had high viral load (mean, 5.0 log copies/mL) and low CD4 cell counts (median, 260 CD4 cells/μL). Protease and/or reverse transcriptase sequences were obtained from 104 (72%) samples. Patients harbored subtypes C (80.8%), G (3.8%), CRF37-cpx (6.7%), untypable (U) (1.0%), and recombinant strains (7.7%) comprising the A, C, D, F, and U clades. There were no major protease inhibitor resistance mutations. Mutations conferring resistance to the nucleoside/nucleotide reverse transcriptase inhibitors and/or nonnucleoside reverse transcriptase inhibitors were found in 4 (4/68; 5.9%) patients. Phylogenetic analysis suggested an imported origin for 2 resistant variants. CONCLUSIONS: The HIV-1 epidemic in Maputo is evolving rapidly in genetic complexity due to the recent introduction of all major subtypes and recombinant forms. Continued surveillance of drug resistance in treated and untreated populations is needed to prevent further transmission of HIV drug-resistant variants and maximize the efficacy of antiretroviral therapy in Maputo. © 2009 by Lippincott Williams & Wilkins.
Authors & Co-Authors
Bártolo, Inês
Portugal, Lisbon
Faculdade de Farmácia, Universidade de Lisboa
Casanovas, José
Mozambique, Maputo
Universidade Eduardo Mondlane
Bastos, Rui
Mozambique, Maputo
Hospital Central de Maputo
Rocha, Cheila
Portugal, Lisbon
Faculdade de Farmácia, Universidade de Lisboa
Abecasis, A. Barroso
Belgium, Leuven
Rega Institute for Medical Research
Folgosa, Elena
Mozambique, Maputo
Universidade Eduardo Mondlane
Mondlane, José
Mozambique, Maputo
Universidade Eduardo Mondlane
Manuel, Rolanda Carmen Rafael
Mozambique, Maputo
Hospital Central de Maputo
Taveira, Nuno
Portugal, Lisbon
Faculdade de Farmácia, Universidade de Lisboa
Portugal, Caparica
Egas Moniz School of Health and Science
Statistics
Citations: 34
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1097/QAI.0b013e3181a24906
ISSN:
15254135
Research Areas
Genetics And Genomics
Health System And Policy
Infectious Diseases
Study Locations
Mozambique